AgilVax’s lead product, AX09, produces antibodies that specifically inhibit the function of xCT, a protein that is overexpressed on numerous tumor types including metastatic breast, colorectal, lung, pancreatic, hepatocellular cancers and glioblastoma.
*
By inhibiting the function of xCT, AX09, has the potential to enhance the effectiveness of current therapies, reduce metastatic spread, and make a dramatic improvement in patient survival.